| abstract |
The present invention relates to solid orally administrable pharmaceutical administration forms comprising 5-chloro-N - ({(5S) -2-oxo-3- [4- (3-oxo-4-morpholinyl) phenyl] - 1,3-oxazolidin-5-yl} -methyl) -2-thiophenecarboxamide (rivaroxaban, active compound (I)), characterized in that a partial amount of the active compound (I) is rapidly released and a partial amount is released in a controlled (modified, delayed, postponed), and to procedures for their preparation, their use as drugs, and their use for prophylaxis, secondary prophylaxis, or treatment of disorders. |